Randomized Trial of Yangxinshi Tablets Added to Standard Treatment for Patients Aged 40-80 with Coronary Heart Disease and Cardiac Dysfunction
Led by SPH Qingdao Growful Pharmacetical Co.,Ltd · Updated on 2025-11-25
2708
Participants Needed
96
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of Yangxinshi tablets in patients with coronary heart disease combined with cardiac dysfunction. This study aims to determine if adding Yangxinshi tablets to standard treatment can reduce heart-related events, enhance exercise capacity, and improve quality of life and mental health. The trial includes 2708 patients and is a Phase 4 randomized controlled study sponsored by SPH Qingdao Growful Pharmaceutical Co., Ltd.
Participants are randomly assigned to one of two groups one group receives conventional treatment plus Yangxinshi tablets 3 tablets taken orally three times a day, while the control group receives conventional treatment alone. Conventional treatment includes drugs such as aspirin, beta-blockers, statins, and others for symptom relief and improving heart outcomes. The treatment continues until a set number of heart-related events occur or the study ends.
Throughout the study, participants undergo regular assessments including measurements of heart events, exercise tolerance, heart function tests, blood markers, and mental health questionnaires over an average of three years. Additional evaluations at 24 and 48 weeks include depression and anxiety scales, echocardiography, and exercise testing. The research team closely monitors safety, quality of life, and heart function throughout the study period.
CONDITIONS
Brief Title
Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
Research Team
H
Han ya ling
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with coronary heart disease, including acute or chronic coronary syndrome, with revascularization decisions made by a doctor
Aged between 40 and 80 years, any sex
NYHA cardiac function class II, III, or IV
NT-proBNP > 125 pg/mL or BNP > 35 pg/mL
Traditional Chinese medicine diagnosis of chest obstruction (qi deficiency and blood stasis syndrome)
Voluntarily consented and signed informed consent form
You will not qualify if you...
STEMI (heart attack) within the past 3 days
Extremely high risk NSTEMI with unstable heart or new/aggravated heart failure
Acute heart attack with cardiogenic shock, mechanical issues, respiratory failure, or multiple organ failure
Severe liver dysfunction, kidney failure (eGFR < 30 mL/min/1.73m2), acute infections, or mental disorders
Drug-resistant hypertension (systolic ≥180 mmHg or diastolic ≥110 mmHg)
Pregnant, lactating, or planning pregnancy during the study
Unable to tolerate 3 months of dual antiplatelet therapy
Allergic or abnormal reactions to study drug or ingredients
Regular use of Yangxinshi or similar traditional medicines in past month
Participation in other clinical drug trials within 3 months
Malignant tumors or conditions with expected survival under 3 years
Deemed unsuitable for the trial by the investigator
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to approximately 3 years
Participants receive conventional treatment for coronary heart disease and cardiac dysfunction. The trial group receives Yangxinshi tablets in addition to conventional treatment, taken orally three times a day. The treatment continues until the expected number of endpoint events is reached or the study ends.
Regular follow-up visits during treatment period
Follow-up
Duration - Up to approximately 3 years
Participants are monitored for clinical events such as ischemic events, heart failure-related events, and quality of life outcomes throughout the study period.
Assessments at 24 and 48 weeks for mental health and cardiac function, and ongoing monitoring until study completion
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Comparing Healing of BioFreedom Drug-Coated Stents and Xience Drug-Eluting Stents in Acute Coronary Syndrome Patients with High Bleeding Risk Using Advanced Imaging
Study of Yiyang Huoluo Decoction Combined with Western Medicine to Treat Coronary Heart Disease and Atherosclerosis in Older Adults
Early Detection of Heart Problems in Adults Who Survived Childhood Cancer Using Advanced Echocardiography
Study of Heart Complications in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
Risk Assessment System for Heart and Kidney Problems in Adults With Coronary Heart Disease and Chronic Kidney Disease Using Lipid Metabolomics
Study of Personalized Prevention Program Effectiveness and Cost in High-Risk Stable Coronary Heart Disease Patients
Effectiveness of Cognitive Behavioural Therapy for Insomnia in Adults With Coronary Heart Disease A Randomized Study With Six Months Follow-up
Building a Multi-Center Database to Study Adults Undergoing Cardiac Surgery with Cardiopulmonary Bypass for Improved Perioperative Outcomes
Evaluating CT Coronary Angiography Versus Standard Angiography in Patients with Previous Coronary Bypass Surgery
A Randomized Study to Reduce Heart Attacks, Stroke, and Hospital Visits
Impact of Personalized Exercise Training on Heart and Lung Function
in Older Adults with Coronary Heart Disease Aged 60 to 75
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Yangxinshi Tablet Improves Exercise Capacity for Patients with Coronary Heart Disease: Results from a Randomized, Double-Blind, Placebo-Controlled, and Multicenter Trial.
Efficacy and safety of yangxinshi versus trimetazidine on exercise tolerance in patients with coronary heart disease after percutaneous coronary intervention: Multicenter, double-blind clinical trial.